Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Novartis
Healthtrust
Teva
AstraZeneca
Accenture
Queensland Health
Cantor Fitzgerald
US Army
US Department of Justice

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,566,729

« Back to Dashboard

Which drugs does patent 7,566,729 protect, and when does it expire?


Patent 7,566,729 protects ESBRIET and is included in two NDAs.

This patent has fifty-four patent family members in thirty-four countries.

Summary for Patent: 7,566,729

Title:Modifying pirfenidone treatment for patients with atypical liver function
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage.
Inventor(s): Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:12/428,393
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,566,729

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,635,707Pirfenidone treatment for patients with atypical liver function► Subscribe
8,609,701Pirfenidone treatment for patients with atypical liver function► Subscribe
8,592,462Pirfenidone treatment for patients with atypical liver function► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,566,729

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria503480► Subscribe
Australia2009313302► Subscribe
Australia2010212371► Subscribe
Australia2011200385► Subscribe
Australia2012205256► Subscribe
BrazilPI0921022► Subscribe
Canada2709997► Subscribe
Canada2765402► Subscribe
China102209543► Subscribe
Colombia6382132► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
Express Scripts
US Army
Federal Trade Commission
Moodys
Mallinckrodt
Chubb
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot